ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies

Ann Hematol. 2022 Mar;101(3):469-484. doi: 10.1007/s00277-022-04761-7. Epub 2022 Jan 20.

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is a primary immune regulatory disorder characterized by benign or malignant lymphoproliferation and autoimmunity. Classically, ALPS is due to mutations in FAS and other related genes; however, recent research revealed that other genes could be responsible for similar clinical features. Therefore, ALPS classification and diagnostic criteria have changed over time, and several ALPS-like disorders have been recently identified. Moreover, mutations in FAS often show an incomplete penetrance, and certain genotypes have been associated to a dominant or recessive inheritance pattern. FAS mutations may also be acquired or could become pathogenic when associated to variants in other genes, delineating a possible digenic type of inheritance. Intriguingly, variants in FAS and increased TCR αβ double-negative T cells (DNTs, a hallmark of ALPS) have been identified in multifactorial autoimmune diseases, while FAS itself could play a potential role in carcinogenesis. These findings suggest that alterations of FAS-mediated apoptosis could trespass the universe of inborn errors of immunity and that somatic mutations leading to ALPS could only be the tip of the iceberg of acquired immunodeficiencies.

Keywords: ALPS; Double-negative T cells; FAS; Immune dysregulation; Lymphoproliferation; Primary immunodeficiencies.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Lymphoproliferative Syndrome / diagnosis
  • Autoimmune Lymphoproliferative Syndrome / genetics*
  • Autoimmune Lymphoproliferative Syndrome / immunology
  • Autoimmunity
  • Humans
  • Mutation*
  • Neoplasms / diagnosis
  • Neoplasms / genetics
  • Neoplasms / immunology
  • fas Receptor / genetics*
  • fas Receptor / immunology

Substances

  • FAS protein, human
  • fas Receptor